Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 120

1.

Dental management considerations for a patient taking dabigatran etexilate: a case report.

Romond KK, Miller CS, Henry RG.

Oral Surg Oral Med Oral Pathol Oral Radiol. 2013 Sep;116(3):e191-5. doi: 10.1016/j.oooo.2013.05.001.

PMID:
23850368
2.
3.

Implications of Dabigatran, a direct thrombin inhibitor, for oral surgery practice.

Davis C, Robertson C, Shivakumar S, Lee M.

J Can Dent Assoc. 2013;79:d74. Review.

4.

[Direct oral thrombin inhibitor, "dabigatran"].

Yasaka M.

Nihon Rinsho. 2013 Jan;71(1):113-8. Review. Japanese.

PMID:
23631181
5.

The untold story of Dabigatran etexilate: alveolar hemorrhage in an elderly patient with interstitial pulmonary fibrosis.

Husari A, Beydoun A, Sheik Ammar A, Maakaron JE, Taher A.

J Thromb Thrombolysis. 2013 Jan;35(1):81-2. doi: 10.1007/s11239-012-0784-9.

PMID:
22843168
6.

[Dabigatran therapy--perioperative management and interpretation of coagulation tests].

Spannagl M, Bauersachs R, Debus ES, Gawaz M, Gerlach H, Haas S, Hach-Wunderle V, Lindhoff-Last E, Riess H, Schellong S, Schinzel H, Bode C.

Hamostaseologie. 2012;32(4):294-305. doi: 10.5482/ha-2012030004. German.

PMID:
23114798
7.

Dabigatran for anticoagulation in atrial fibrillation - early clinical experience in a hospital population and comparison to trial data.

Michel J, Mundell D, Boga T, Sasse A.

Heart Lung Circ. 2013 Jan;22(1):50-5. doi: 10.1016/j.hlc.2012.09.002.

PMID:
23058974
8.

Modeling of the impact on health outcomes of the use of dabigatran in patients with atrial fibrillation.

Chevalier J, Giroud M, de Pouvourville G.

Cerebrovasc Dis. 2013;35(4):320-6. doi: 10.1159/000347074.

PMID:
23615428
9.

A comparison of bleeding complications post-ablation between warfarin and dabigatran.

Snipelisky D, Kauffman C, Prussak K, Johns G, Venkatachalam K, Kusumoto F.

J Interv Card Electrophysiol. 2012 Oct;35(1):29-33. doi: 10.1007/s10840-012-9708-z.

PMID:
22869389
10.

The Long-Term Multicenter Observational Study of Dabigatran Treatment in Patients With Atrial Fibrillation (RELY-ABLE) Study.

Connolly SJ, Wallentin L, Ezekowitz MD, Eikelboom J, Oldgren J, Reilly PA, Brueckmann M, Pogue J, Alings M, Amerena JV, Avezum A, Baumgartner I, Budaj AJ, Chen JH, Dans AL, Darius H, Di Pasquale G, Ferreira J, Flaker GC, Flather MD, Franzosi MG, Golitsyn SP, Halon DA, Heidbuchel H, Hohnloser SH, Huber K, Jansky P, Kamensky G, Keltai M, Kim SS, Lau CP, Le Heuzey JY, Lewis BS, Liu L, Nanas J, Omar R, Pais P, Pedersen KE, Piegas LS, Raev D, Smith PJ, Talajic M, Tan RS, Tanomsup S, Toivonen L, Vinereanu D, Xavier D, Zhu J, Wang SQ, Duffy CO, Themeles E, Yusuf S.

Circulation. 2013 Jul 16;128(3):237-43. doi: 10.1161/CIRCULATIONAHA.112.001139.

11.

Adherence to anticoagulant treatment with dabigatran in a real-world setting.

Schulman S, Shortt B, Robinson M, Eikelboom JW.

J Thromb Haemost. 2013 Jul;11(7):1295-9. doi: 10.1111/jth.12241.

13.

Balancing the benefits and risks of 2 doses of dabigatran compared with warfarin in atrial fibrillation.

Eikelboom JW, Connolly SJ, Hart RG, Wallentin L, Reilly P, Oldgren J, Yang S, Yusuf S.

J Am Coll Cardiol. 2013 Sep 3;62(10):900-8. doi: 10.1016/j.jacc.2013.05.042.

14.

Relation between dabigatran concentration, as assessed using the direct thrombin inhibitor assay, and activated clotting time/activated partial thromboplastin time in patients with atrial fibrillation.

Okubo K, Kuwahara T, Takagi K, Takigawa M, Nakajima J, Watari Y, Nakashima E, Yamao K, Fujino T, Tsutsui H, Takahashi A.

Am J Cardiol. 2015 Jun 15;115(12):1696-9. doi: 10.1016/j.amjcard.2015.03.013.

PMID:
25918026
15.

Dabigatran for stroke prevention in atrial fibrillation.

Hohnloser SH, Diener HC.

Hamostaseologie. 2012;32(3):216-20. doi: 10.5482/ha-1196.

PMID:
22739760
16.

Dabigatran in the peri-procedural period for radiofrequency ablation of atrial fibrillation: efficacy, safety, and impact on duration of hospital stay.

Imamura K, Yoshida A, Takei A, Fukuzawa K, Kiuchi K, Takami K, Takami M, Itoh M, Fujiwara R, Suzuki A, Nakanishi T, Yamashita S, Matsumoto A, Hirata K.

J Interv Card Electrophysiol. 2013 Sep;37(3):223-31. doi: 10.1007/s10840-013-9801-y.

17.
18.

Continuous warfarin versus periprocedural dabigatran to reduce stroke and systemic embolism in patients undergoing catheter ablation for atrial fibrillation or left atrial flutter.

Kaiser DW, Streur MM, Nagarakanti R, Whalen SP, Ellis CR.

J Interv Card Electrophysiol. 2013 Sep;37(3):241-7. doi: 10.1007/s10840-013-9793-7.

PMID:
23625091
19.

Adherence and outcomes of patients treated with dabigatran: pharmacist-managed anticoagulation clinic versus usual care.

Lee PY, Han SY, Miyahara RK.

Am J Health Syst Pharm. 2013 Jul 1;70(13):1154-61. doi: 10.2146/ajhp120634.

PMID:
23784163
20.

Periprocedural dabigatran in atrial fibrillation ablation: a new kid on the block.

Pelargonio G, Perna F.

J Cardiovasc Electrophysiol. 2013 Aug;24(8):866-8. doi: 10.1111/jce.12168. No abstract available.

PMID:
23647979
Items per page

Supplemental Content

Support Center